Vikram Narayan, MD, Discusses Nadofaragene, Anti-Adenovirus Antibodies and Cystectomy for Patients with NMIBC

Video

Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.

Vikram Narayan, MD, spoke with CancerNetwork to expand on research published at the 21st Annual Meeting of the Society of Urologic Oncology to treat patients with non-muscle invasive bladder cancer (NMIBC).

Transcription:

One of the other projects we looked at was to measure anti-adenovirus antibodies in patients before each of the treatment doses. So, again, this is an adenovirus-based therapy. We measured anti-adenovirus antibodies in the patients, and we looked to see if that correlated to treatment response. What we found was that significantly more patients who had a 2-fold greater than baseline level of adenovirus antibodies had achieved a complete response compared to non-responders. This may have implications in terms of being able to predict who treatment responders might be and we’re investigating that further.

The last poster that we looked at looked specifically at the question of cystectomy. So, as you know, this is meant to be a bladder sparing treatment option. One question is, well does it prevent or prolong the time to cystectomy, if at all? What our analysis showed was that, among those who eventually underwent cystectomy, patients who had achieved a complete response having received nadofaragene managed to hold off significantly longer than patients who had not achieved a complete response in terms of time to cystectomy. That was found in both groups. There were 2 groups in the study, a CIS group and a non-CIS group, and both groups that was identified in.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Related Content